
    
      This phase III study is assessing the drug's safety and is aiming to demonstrate efficacy of
      repeated intratympanic AM-101 injections in the treatment of acute peripheral tinnitus (up to
      3 months (Stratum A), or between >3 and 6 months (Stratum B) from onset).
    
  